期刊
CURRENT OPINION IN PHARMACOLOGY
卷 35, 期 -, 页码 20-29出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2017.04.008
关键词
-
资金
- Instituto de Salud Carlos III, an organisation of the Ministerio de Economia y Competitividad [SAF2014-55942-R]
- FEDER funds/European Regional Development Fund (ERDF)- a way to build Europe
- Multiple Myeloma Research Foundation (MMRF)
- Asociacion Espanola Contra el Cancer (AECC)
Myeloid cells are extremely plastic as they respond and terminally differentiate into a plethora of functional types, in the blood or tissues, in response to a variety of growth factors, cytokines and pathogenic molecules. This plasticity is also manifested by the subversion of normal differentiation into the aberrant generation of a variety of tolerogenic myeloid cells in the tumoral microenvironment, where a variety of factors are released. Epigenetic mechanisms are in great part responsible for the plasticity of myeloid cells both under physiological and tumoral conditions. The development of compounds that inhibit epigenetic enzymes provides novel therapeutic opportunities to intercept the crosstalk between cancer cells and host myeloid cells. Here, we summarize our current knowledge on the myeloid cell types generated in the cancer environment, the factors and epigenetic enzymes participating in these processes and propose a number of potential targets for future pharmacological use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据